Long-term Survival Outcomes With Intravesical Nanoparticle Albumin-bound Paclitaxel for Recurrent Non–muscle-invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy

Update on the guideline of guidelines: non‐muscle‐invasive bladder cancer

“…In BCG‐unresponsive patients, combination treatments with gemcitabine‐docetaxel and nab‐paclitaxel show a 54% and 36% CRR at 1 and 3.5 years, respectively. While sequential gemcitabine plus mitomycin resulted in a 30–40% recurrence‐free survival at a median 2‐year follow‐up, these regimens mostly originate from single‐institution, non‐randomized, retrospective studies, and should be viewed as investigational and a potential option when BCG is unavailable or RC is not feasible.…”

Non Muscle-Invasive Bladder Cancer (NMIBC)

“…After adding albumin (creating nabpaclitaxel), the nanoparticle's solubility is increased fivefold and can use albumin receptor-mediated transport for increased delivery to tumor cells. 38,82 Long-term follow-up data from the Phase II trial (medium 41-month follow-up) on 28 patients showed cancer-specific survival rate of 91% (18% disease free) at 5 years. 82 Some drug targets appear promising but their short half-lives limit exposure to the urothelium and render them ineffective.…”

New therapies in nonmuscle invasive bladder cancer treatment

“…After adding albumin (creating nab-paclitaxel), the nanoparticle's solubility is increased fivefold and can use albumin receptor-mediated transport for increased delivery to tumor cells. [ 38 82 ] Long-term follow-up data from the Phase II trial (medium 41-month follow-up) on 28 patients showed cancer-specific survival rate of 91% (18% disease free) at 5 years. [ 82 ]…”

“…[ 38 82 ] Long-term follow-up data from the Phase II trial (medium 41-month follow-up) on 28 patients showed cancer-specific survival rate of 91% (18% disease free) at 5 years. [ 82 ]…”